HOME >> BIOLOGY >> NEWS
Updated Iraq survey affirms earlier mortality estimates

As many as 654,965 more Iraqis may have died since hostilities began in Iraq in March 2003 than would have been expected under pre-war conditions, according to a survey conducted by researchers at the Johns Hopkins Bloomberg School of Public Health and Al Mustansiriya University in Baghdad. The deaths from all causes--violent and non-violent--are over and above the estimated 143,000 deaths per year that occurred from all causes prior to the March 2003 invasion.

The estimates were derived from a nationwide household survey of 1,849 households throughout Iraq conducted between May and July 2006. The results are consistent with the findings of an October 2004 study of Iraq mortality conducted by the Hopkins researchers. Also, the findings closely reflect the increased mortality trends reported by other organizations that utilized passive methods of counting mortality, such as counting bodies in morgues or deaths reported by the news media. The study is published in the October 12, 2006, online edition of the peer-reviewed scientific journal, The Lancet.

"As we found with our previous survey, the majority of deaths in Iraq are due to violence--although we also saw a small increase in deaths from non-violent causes, such as heart disease, cancer and chronic illness. Gunshots were the primary cause of violent deaths. To put these numbers in context, deaths are occurring in Iraq now at a rate more than three times that from before the invasion of March 2003," said Gilbert Burnham, MD, PhD, lead author of the study and co-director of the Bloomberg School's Center for Refugee and Disaster Response. "Our total estimate is much higher than other mortality estimates because we used a population-based, active method for collecting mortality information rather than passive methods that depend on counting bodies or tabulated media reports of violent deaths. Though the numbers differ, the trend in increasing numbers of deaths closely follows that measured by t
'"/>

Contact: Tim Parsons
paffairs@jhsph.edu
410-955-6878
Johns Hopkins University Bloomberg School of Public Health
11-Oct-2006


Page: 1 2 3

Related biology news :

1. Updated data on novel HPV vaccine confirms efficacy in large population
2. New survey documents the headaches of computerized medicine
3. Satellite survey links tropical park fires with poverty and corruption
4. Plasma science decadal survey
5. Global survey of lizards reveals greater abundance of animals on islands than on mainland ecosystems
6. Rutgers survey examines public responses to the recent spinach recall
7. Americans support for embryonic stem cell research declines, VCU Life Sciences survey shows
8. MIT survey: Climate change tops Americans environmental concerns
9. Science survey ranks top Biopharma employers
10. Large European survey reveals critical gaps in breast cancer patient education and communication
11. First surveys of Tanzanian mountains reveal 160+ animal species, including new & endemic

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Updated Iraq survey affirms earlier mortality estimates

(Date:5/19/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 This year ... especially for lawns. US Patented Pearl’s Premium Ultra ... lawns around the country that are coming out of ... addresses a number of major global concerns related to ... “non-grass” grass – the alternative to the standard, water-wasting, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
Cached News: